Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation

American Journal of Transplantation

Volumn 10, Issue 9, 2010, Pages 2082-2091

  Turgeon, N A ^a   Avila, J G ^a   Cano, J A ^a   Hutchinson, J J ^a   Badell, I R ^a   Page, A J ^a   Adams, A B ^a   Sears, M H ^a   Bowen, P H ^a   Kirk, A D ^a   Pearson, T C ^a   Larsen, C P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; immunosuppressive therapy; islet transplantation

Indexed keywords

DACLIZUMAB; EFALIZUMAB; HEMOGLOBIN A1C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCISIONAL HERNIA; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LEUKOPENIA; MALE; MOUTH ULCER; ORGAN DONOR; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDIES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 77956145092     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03212.x     Document Type: Article

References (21)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 : 1047 1053.
2. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes 1997 46 : 271 286.
3. Jacqueminet S, Masseboeuf N, Rolland M, Grimaldi A, Sachon C. Limitations of the so-called "intensified" insulin therapy in type 1 diabetes mellitus. Diabetes Metab 2005 31 (4 Pt 2 4S45 4S50.
4. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 343 : 230 238.
5. Shapiro AM, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006 355 : 1318 1330.
6. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006 6 : 27 36.
7. Moriyama H, Yokono K, Amano K et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol 1996 157 : 3737 3743.
8. Herold KC, Vezys V, Gage A, Montag AG. Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cell Immunol 1994 157 : 489 500.
9. Chowdhury SA, Nagata M, Yamada K et al. Tolerance mechanisms in murine autoimmune diabetes induced by anti-ICAM-1/LFA-1 mAb and anti-CD8 mAb. Kobe J Med Sci 2002 48 : 167 175.
10. Poston RS, Robbins RC, Chan B et al. Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation 2000 69 : 2005 2013.
11. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008 158 : 1107 1116.
12. Froud T, Ricordi C, Baidal DA et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005 5 : 2037 2046.
13. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes 1988 37 : 413 420.
14. Ichii H, Pileggi A, Molano RD et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005 5 : 21 30.
15. Bray RA, Lebeck LK, Gebel HM. The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities. Transplantation 1989 48 : 834 840.
16. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992 39 : 225 235.
17. Tambur AR, Bray RA, Takemoto SK et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000 70 : 1055 1059.
18. Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010 10 : 535 546.
19. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: Assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008 67 (Suppl 3 iii64 iii65.
20. Kirk AD, Cherikh WS, Ring M et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007 7 : 2619 2625.
21. Neff RT, Hurst FP, Falta EM et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008 86 : 1474 1478.